Latest C-peptide Stories
SAN FRANCISCO, Sept. 14 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc.
MINNEAPOLIS, Aug. 18 /PRNewswire/ -- Exsulin Corporation today announced milestones achieved and immediate plans to move forward as a well supported Minnesota-based company dedicated to the development of regeneration therapies for the treatment of diabetes mellitus.
CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S.
Mayo Clinic cardiology researchers have found a peptide that helps preserve and improve kidney function during heart failure, without affecting blood pressure.
SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, received notification from the U.S.
- Company plans initiation of clinical studies; Data to be presented at AACR - BATON ROUGE, La., April 21 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today presented positive results from the Company's preclinical program that support the initiation of clinical trials in cancer.
The majority of patients with type 1 diabetes who underwent a certain type of stem cell transplantation became insulin free, several for more than three years, with good glycemic control, and also increased C-peptide levels, an indirect measure of beta-cell function, according to a study in the April 15 issue of JAMA, a theme issue on diabetes.
HENNIGSDORF, Germany, March 6 /PRNewswire/ -- B-R-A-H-M-S Aktiengesellschaft today announced it has submitted 510(k) file to the U.S. Food and Drug Administration (FDA) to market its patented B-R-A-H-M-S MR-proANP Kryptor Test. Atrial Natriuretic Peptide (ANP) is predominantly produced in the atrium of the heart and comprises 98% of the natriuretic peptides in the circulation.
- Additional Pipeline Product Agreement Executed to Support ConjuChem's R&D Efforts - MONTREAL and BAGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies Inc.
Aegis Therapeutics LLC announced today that preclinical data was presented at the 2008 International Congress of Endocrinology in Rio de Janeiro, Brasil demonstrating that its Intravail(R) formulation technology provides unmatched non-invasive delivery of the OB-3 peptide, a peptide previously shown to control weight gain and glucose levels in an animal model of diabetes.
- Pertaining to the surface or end opposite to the mouth in a radiate animal.